Wall Street analysts expect that Quest Diagnostics Inc (NYSE:DGX) will report $1.72 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Quest Diagnostics’ earnings, with the highest EPS estimate coming in at $1.79 and the lowest estimate coming in at $1.65. Quest Diagnostics reported earnings of $1.68 per share in the same quarter last year, which would indicate a positive year over year growth rate of 2.4%. The firm is scheduled to issue its next earnings results on Tuesday, October 22nd.

On average, analysts expect that Quest Diagnostics will report full-year earnings of $6.50 per share for the current fiscal year, with EPS estimates ranging from $6.45 to $6.56. For the next fiscal year, analysts expect that the business will report earnings of $6.80 per share, with EPS estimates ranging from $6.72 to $6.90. Zacks’ EPS averages are an average based on a survey of analysts that follow Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.73 EPS for the quarter, topping the consensus estimate of $1.69 by $0.04. Quest Diagnostics had a return on equity of 15.05% and a net margin of 9.64%. The firm had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter last year, the company earned $1.75 earnings per share. The business’s revenue for the quarter was up 1.8% compared to the same quarter last year.

Several brokerages have recently issued reports on DGX. Evercore ISI reiterated a “buy” rating and issued a $108.00 price objective on shares of Quest Diagnostics in a research note on Thursday, August 8th. Canaccord Genuity increased their price objective on shares of Quest Diagnostics from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Mizuho set a $110.00 price objective on shares of Quest Diagnostics and gave the stock a “buy” rating in a research note on Monday, May 20th. JPMorgan Chase & Co. increased their price objective on shares of Quest Diagnostics from $100.00 to $111.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, ValuEngine upgraded shares of Quest Diagnostics from a “sell” rating to a “hold” rating in a research note on Wednesday, April 24th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $104.44.

In other news, insider Mark Guinan sold 73,005 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $100.00, for a total value of $7,300,500.00. Following the completion of the transaction, the insider now directly owns 139,022 shares in the company, valued at $13,902,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Stephen H. Rusckowski sold 244,565 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $100.00, for a total transaction of $24,456,500.00. Following the completion of the transaction, the chairman now owns 457,614 shares of the company’s stock, valued at $45,761,400. The disclosure for this sale can be found here. 1.86% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of DGX. Berman Capital Advisors LLC grew its stake in Quest Diagnostics by 47.7% during the 2nd quarter. Berman Capital Advisors LLC now owns 319 shares of the medical research company’s stock worth $32,000 after buying an additional 103 shares during the last quarter. Financial Advantage Inc. grew its stake in shares of Quest Diagnostics by 0.3% during the 2nd quarter. Financial Advantage Inc. now owns 30,316 shares of the medical research company’s stock valued at $3,086,000 after buying an additional 104 shares during the period. IFG Advisory LLC grew its stake in shares of Quest Diagnostics by 2.5% during the 2nd quarter. IFG Advisory LLC now owns 4,233 shares of the medical research company’s stock valued at $430,000 after buying an additional 105 shares during the period. SeaCrest Wealth Management LLC grew its stake in shares of Quest Diagnostics by 4.5% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,520 shares of the medical research company’s stock valued at $257,000 after buying an additional 108 shares during the period. Finally, United Capital Financial Advisers LLC grew its stake in shares of Quest Diagnostics by 0.5% during the 2nd quarter. United Capital Financial Advisers LLC now owns 21,547 shares of the medical research company’s stock valued at $2,194,000 after buying an additional 108 shares during the period. Institutional investors and hedge funds own 90.89% of the company’s stock.

Shares of NYSE:DGX traded down $0.32 during trading on Thursday, hitting $102.83. 728,811 shares of the company’s stock were exchanged, compared to its average volume of 996,379. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.82 and a quick ratio of 0.77. Quest Diagnostics has a 52-week low of $78.95 and a 52-week high of $111.54. The business’s 50-day simple moving average is $101.38 and its 200 day simple moving average is $95.03. The company has a market cap of $13.75 billion, a price-to-earnings ratio of 16.30, a PEG ratio of 2.07 and a beta of 0.88.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Shareholders of record on Friday, October 4th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.06%. The ex-dividend date of this dividend is Thursday, October 3rd. Quest Diagnostics’s dividend payout ratio (DPR) is 33.60%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.